<DOC>
	<DOCNO>NCT02792413</DOCNO>
	<brief_summary>Aim study evaluate population old osteoporotic chronic kidney disease female effect denosumab : - bone mineral density ( femoral T-score ) 24 month - bone mineral density evolution ( femoral T-score ) 24 month follow-up - bone mineral density evolution ( lumbar T-score ) 24 month follow-up - coronary abdominal aorta calcification score evolution 24 month follow-up - parameter bone remodelling ( OPG , RANKL , sclerostin , DKK-1 ) , mineral calcium metabolism ( FGF23 Ct , Klotho , PTH , 25 ( OH ) vitamin D3 , phosphorus , calcium , bone alklaline phosphatase , osteocalcin , CTX ) , inflammation ( CRP ) 24 month follow-up - cardiovascular morbidity ( cardiovascular event ) mortality 24 month follow-up - tolerance 24 month follow-up</brief_summary>
	<brief_title>Study Evaluating Denosumab Bone Vascular Metabolism Osteoporotic Chronic Kidney Disease</brief_title>
	<detailed_description>Aim study evaluate population old osteoporotic chronic kidney disease female effect denosumab : - bone mineral density ( femoral T-score ) ( bone densitometry ) 24 month - bone mineral density evolution ( femoral T-score ) ( bone densitometry ) 24 month follow-up - bone mineral density evolution ( lumbar T-score ) ( bone densitometry ) 24 month follow-up - coronary abdominal aorta calcification score evolution ( multiple detector compute tomography plain abdominal X-ray ) 24 month follow-up - parameter bone remodelling ( OPG , RANKL , sclerostin , DKK-1 ) , mineral calcium metabolism ( FGF23 Ct , Klotho , PTH , 25 ( OH ) vitamin D3 , phosphorus , calcium , bone alklaline phosphatase , osteocalcin , CTX ) , inflammation ( CRP ) 24 month follow-up - cardiovascular morbidity ( cardiovascular event ) mortality 24 month follow-up - tolerance 24 month follow-up</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Patient female 65 year old Chronic kidney disease stage 5 patient , hemodialyzed extracorporeal treatment least 3 month History vertebral fracture Cinacalcet treatment Substitutive hormonal treatment Calcium phosphate balance ( PTH , 25 ( OH ) vitamin D3 , Calcium , phosphate ) outside KDIGO guideline Hypersensibility active substance one excipients denosumab</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>anti-RANK ligand antibody</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>vascular calcification</keyword>
</DOC>